Chemopreventive effect of Korean Angelica root extract on TRAMP carcinogenesis and integrative "omic" profiling of affected neuroendocrine carcinomas

Molecular Carcinogenesis

Volumn 54, Issue 12, 2015, Pages 1567-1583

  Zhang, Jinhui ^a   Wang, Lei ^b   Zhang, Yong ^a   Li, Li ^a   Tang, Suni ^a   Xing, Chengguo ^b   Kim, Sung Hoon ^c   Jiang, Cheng ^a   Lü, Junxuan ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Kyung Hee University   (South Korea)

Author keywords

Angelica gigas Nakai; Microarray; Prostate cancer; Proteomics; TRAMP model; Transcriptomics

Indexed keywords

ANGELICA GIGAS NAKAI ROOT ETHANOL EXTRACT; ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MESSENGER RNA; ONCOFETAL ANTIGEN; PLANT EXTRACT; TRANSCRIPTOME; UNCLASSIFIED DRUG; WNT PROTEIN; PROTEOME;

ANGELICA GIGAS; ANGIOGENESIS; ANIMAL CELL; ANIMAL EUTHANASIA; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL MOTILITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DATA MINING; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION; IMMUNE RESPONSE; INFLAMMATION; MALE; MAST CELL; MEDICINAL PLANT; MORPHOGENESIS; MOUSE; MOUSE MODEL; MULTIPLE CANCER; MUSCLE DEVELOPMENT; NERVE CELL; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE; PROTEOMICS; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; WILD TYPE; WNT SIGNALING PATHWAY; ADENOCARCINOMA; ANGELICA; ANIMAL; C57BL MOUSE; CARCINOMA, NEUROENDOCRINE; CHEMISTRY; DISEASE MODEL; DOWN REGULATION; DRUG EFFECTS; NEOVASCULARIZATION, PATHOLOGIC; PLANT ROOT; PROCEDURES; PROSTATIC NEOPLASMS; TRANSGENIC MOUSE; UPREGULATION;

ADENOCARCINOMA; ANGELICA; ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOGENESIS; CARCINOMA, NEUROENDOCRINE; CHEMOPREVENTION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PLANT EXTRACTS; PLANT ROOTS; PROSTATIC NEOPLASMS; PROTEOME; SIGNAL TRANSDUCTION; TRANSCRIPTOME; UP-REGULATION;

EID: 84944530017     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22230     Document Type: Article

References (46)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012; 62:10-29.
2. Zhang J, Li L, Jiang C, et al. Anti-cancer and other bioactivities of Korean Angelica gigas nakai (AGN) and its major pyranocoumarin compounds. Anticancer Agents Med Chem 2012; 12:1239-1254.
3. Ahn MJ, Lee MK, Kim YC, Sung SH. The simultaneous determination of coumarins in Angelica gigas root by high performance liquid chromatography-diode array detector coupled with electrospray ionization/mass spectrometry. J Pharm Biomed Anal 2008; 46:258-266.
4. Lu J, Kim SH, Jiang C, Lee H, Guo J. Oriental herbs as a source of novel anti-androgen and prostate cancer chemopreventive agents. Acta Pharmacol Sin 2007; 28:1365-1372.
5. Jiang C, Lee HJ, Li GX, et al. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: Identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Cancer Res 2006; 66:453-463.
6. Guo J, Jiang C, Wang Z, et al. A novel class of pyranocoumarin anti-androgen receptor signaling compounds. Mol Cancer Ther 2007; 6:907-917.
7. Lee HJ, Lee EO, Lee JH, et al. In vivo anti-cancer activity of Korean Angelica gigas and its major pyranocoumarin decursin. Am J Chin Med 2009; 37:127-142.
8. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995; 92:3439-3443.
9. Zhang J, Wang L, Zhang Y, Lü J. Lobe-Specific Carcinogenesis in the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) Mouse Model. 2013.
10. Zhang J, Wang L, Zhang Y, et al. Lobe-specific proteome changes in the dorsal-lateral and ventral prostate of TRAMP mice versus wild-type mice. Proteomics 2011; 11:2542-2549.
11. Wang L, Zhang J, Zhang Y, et al. Lobe-specific lineages of carcinogenesis in the transgenic adenocarcinoma of mouse prostate and their responses to chemopreventive selenium. Prostate 2011; 71:1429-1440.
12. Wang L, Bonorden MJ, Li GX, et al. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev Res 2009; 2:484-495.
13. Zhang J, Wang L, Anderson LB, et al. Proteomic profiling of potential molecular targets of methyl-selenium compounds in the transgenic adenocarcinoma of mouse prostate model. Cancer Prev Res 2010; 3:994-1006.
14. Zhang J, Wang L, Li G, et al. Mouse prostate proteomes are differentially altered by supranutritional intake of four selenium compounds. Nutr Cancer 2011; 63:778-789.
15. Zhang J, Nkhata K, Shaik AA, et al. Mouse prostate proteome changes induced by oral pentagalloylglucose treatment suggest targets for cancer chemoprevention. Curr Cancer Drug Targets 2011; 11:787-798.
16. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protoc 2009; 4:44-57.
17. Tang S, Zhang Y, Jiang P, et al. A paradigm of carcinogenesis lineage specificities of cancer chemoprevention: Korean Angelica and its pyranocoumarins in the transgenic adenocarcinoma of mouse prostate model. Proc AACR 2013; Abstract #LB-184.
18. Dow JK, deVere White RW. Fibroblast growth factor 2: Its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. Urology 2000; 55:800-806.
19. Giri D, Ropiquet F, Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 1999; 5:1063-1071.
20. Huss WJ, Barrios RJ, Foster BA, Greenberg NM. Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression. Prostate 2003; 54:8-16.
21. Polnaszek N, Kwabi-Addo B, Peterson LE, et al. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res 2003; 63:5754-5760.
22. Singh RP, Raina K, Sharma G, Agarwal R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res 2008; 14:7773-7780.
23. Lin JF, Xu J, Tian HY, et al. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. Int J Cancer 2007; 121:2596-2605.
24. Huang HC, Zheng S, VanBuren V, Zhao Z. Discovering disease-specific biomarker genes for cancer diagnosis and prognosis. Technol Cancer Res Treat 2010; 9:219-230.
25. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18:11-22.
26. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 2011; 68:3033-3046.
27. Jung MH, Lee SH, Ahn EM, Lee YM. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway. Carcinogenesis 2009; 30:655-661.
28. Bullard RS, Gibson W, Bose SK, et al. Functional analysis of the host defense peptide human beta defensin-1: New insight into its potential role in cancer. Mol Immunol 2008; 45:839-848.
29. Kela I, Harmelin A, Waks T, et al. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors. The Prostate 2009; 69:1034-1044.
30. Haram KM, Peltier HJ, Lu B, et al. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy. The Prostate 2008; 68:1517-1530.
31. Yip PY, Kench JG, Rasiah KK, et al. Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer. The Prostate 2011; 71:1638-1645.
32. Henshall SM, Horvath LG, Quinn DI, et al. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst 2006; 98:1420-1424.
33. Morgenbesser SD, McLaren RP, Richards B, et al. Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model. Prostate 2007; 67:83-106.
34. Komiya A, Suzuki H, Imamoto T, et al. Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 2009; 16:37-44.
35. Sun LC, Mackey LV, Luo J, Fuselier JA, Coy DH. Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice. Clin Med 2008; 2:491-499.
36. Pittoni P, Tripodo C, Piconese S, et al. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res 2011; 71:5987-5997.
37. Lenferink AE, Cantin C, Nantel A, et al. Transcriptome profiling of a TGF-beta-induced epithelial-to-mesenchymal transition reveals extracellular clusterin as a target for therapeutic antibodies. Oncogene 2010; 29:831-844.
38. Son SH, Park KK, Park SK, et al. Decursin and decursinol from angelica gigas inhibit the lung metastasis of murine colon carcinoma. Phytother Res 2011; 25:959-964.
39. Wang S, Gao J, Lei Q, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cells 2003; 4:209-221.
40. Wesley UV, McGroarty M, Homoyouni A. Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res 2005; 65:1325-1334.
41. Giuliani R, Bastaki M, Coltrini D, Presta M. Role of endothelial cell extracellular signal-regulated kinase1/2 in urokinase-type plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2. J Cell Sci 1999; 112:2597-2606.
42. Ma S, Chan YP, Woolcock B, et al. DNA fingerprinting tags novel altered chromosomal regions and identifies the involvement of SOX5 in the progression of prostate cancer. International journal of cancer. J Int Cancer 2009; 124:2323-2332.
43. Rao S, Lyons LS, Fahrenholtz CD, et al. A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer. Oncogene 2012; 31:716-727.
44. Zhang W, Chen Y, Swift MR, et al. Effect of FGF-binding protein 3 on vascular permeability. J Biol Chem 2008; 283:28329-28337.
45. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6:1-6.
46. Son SH, Kim MJ, Chung WY, et al. Decursin and decursinol inhibit VEGF-induced angiogenesis by blocking the activation of extracellular signal-regulated kinase and c-Jun N-terminal kinase. Cancer Lett 2009; 280:86-92.